RSV mAb
Respiratory Syncytial Virus Infection
PreclinicalActive
Key Facts
Indication
Respiratory Syncytial Virus Infection
Phase
Preclinical
Status
Active
Company
About Trellis Bioscience
Trellis Bioscience is a private, pre-revenue biotech founded in 2018 that has developed the CellSpot™ platform for high-throughput discovery of native human monoclonal antibodies from healthy donors. The company's most advanced program, TRL1068, has demonstrated clinical proof-of-concept in a Phase 1 trial for reducing biofilm burden in prosthetic joint infections, a significant unmet medical need. Beyond infectious disease, Trellis has also discovered antibodies against immune checkpoint modulators and tumor-associated antigens for oncology, which are being advanced by partner Relevant Biosciences. The company is supported by non-dilutive funding from partnerships like CARB-X.
View full company profileTherapeutic Areas
Other Respiratory Syncytial Virus Infection Drugs
| Drug | Company | Phase |
|---|---|---|
| RSV Vaccine | VLP Biotech | Pre-clinical |
| VELO RSV Test | LEX Diagnostics | Development |
| Intranasal RSV Vaccine | BioComo | Preclinical |